TITLE

SANOFI-AVENTIS/REGENERON EXPAND VEGF TRAP PACT TO JAPAN

PUB. DATE
February 2006
SOURCE
Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Sanofi-Aventis and Regeron Pharmaceuticals Inc. have expanded their Vascular Endothelial Growth Factor (VEGF) Trap collaboration agreement to include Japan. Joint development and commercialization of the VEGF Trap throughout the world; Remuneration for the inclusion of Japan into the VEGF Trap collaboration; Clinical information on VEGF.
ACCESSION #
20451861

 

Related Articles

  • Regeneron, Sanofi-Aventis Start Two Phase III Aflibercept Trials. Morrison, Trista // BioWorld Today;8/24/2007, Vol. 18 Issue 165, p1 

    The article reports that the Phase III trials with aflibercept or VEGF Trap in prostate cancer and non-small cell lung cancer (NSCLC) were initiated by Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis Group. Chief Scientific Officer of Regeneron, George Yancopoulos, said that the major...

  • SANOFI-AVENTIS/REGENERON EXPAND VEGF TRAP PACT TO JAPAN.  // Worldwide Videotex Update;Feb2006, Vol. 25 Issue 2, p117 

    The article reports on the changes made to the Vascular Endothelial Growth Factor (VEGF) Trap collaboration agreement by Sanofi-Aventis and Regeneron Pharmaceuticals Inc. Sanofi-Aventis will pay 100% of VEGF Trap development expenses under the collaboration agreement. The role of VEGF is to...

  • In the news….  // Hudson Valley Business Journal;1/9/2006, Vol. 17 Issue 1, p8 

    The article offers news briefs related to the field of business. The UBS/Gallup Index of Investor Optimism indicates an increase in investor optimism in December over November. Over the past seven years, December index has been higher than November index. This suggests an increase in optimism...

  • Sanofi, Regeneron Cozying Up: More Antibody Cash Long Term. Osborne, Randy // BioWorld Today;11/11/2009, Vol. 20 Issue 218, p1 

    The article reports on the expansion of a deal between pharmaceutical companies Sanofi-Aventis and Regeneron Pharmaceuticals Inc. that would add five years to the arrangement. As part of the new terms of the deal, Sanofi will increase its funding from 100 million U.S. dollars to 160 million U.S....

  • Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial.  // BioWorld Today;9/14/2009, Vol. 20 Issue 176, p1 

    This article reports on the decision of Regeneron Pharmaceuticals Inc. and partner Sanofi-aventis Group to discontinue their Phase III trial of aflibercept plus gemcitabine versus placebo plus gemcitabine for the first-line therapy of metastatic pancreatic cancer. According to an independent...

  • Aventis to pay Regeneron $510 million for anti-angiogenesis compound.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p18 

    Reports that Aventis SA has agreed to pay Regeneron Pharmaceuticals Inc. to acquire an experimental cancer therapy. Global agreement to develop and commercialize Vascular Endothelial Growth Factor Trap; Terms of the deal; Sharing of promotion rights and profits.

  • Regeneron: VEGF Trap catches Aventis' interest.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p15 

    Discusses global partnership between Aventis SA and Regeneron Pharmaceuticals Inc. to develop and commercialize VEGF Trap, a protein-based antagonist for vascular endothelial growth factor. Mechanism of action; Outcomes of a phase I clinical trial for VEGF Trap for various solid tumors and...

  • Financings Roundup.  // BioWorld Today;12/21/2007, Vol. 18 Issue 247, p4 

    The article reports on the sale of 12 million shares of common stock by Regeneron Pharmaceutical Inc. The stocks are priced at $26 each and were sold to Sanofi-Aventis Group which forms part of the companies' potential $ 1 billion collaboration. This would increase Sanofi's ownership in...

  • Regeneron Signs Sanofi To Potential $1B Collaboration. Young, Donna // BioWorld Today;11/30/2007, Vol. 18 Issue 232, p1 

    The article reports on the collaboration of Regeneron Pharmaceuticals Inc. and Sanofi-Aventis to discover, develop and commercialize human therapeutic antibodies in a cash and stock deal potentially worth $1 billion. Under the terms of the partnership, Sanofi will increase its ownership of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics